5 current cancer treatment or research opportunities
About Colorado Animal Specialty & Emergency (CASE)
Colorado Animal Specialty & Emergency (CASE) is the participating hospital named in the current study listing below. The hospital is part of the Ethos Veterinary Health network, while Ethos Discovery coordinates the research program. Screening, enrollment and required visits are handled by the participating hospital; owners should confirm that the location is still enrolling before making travel plans.
Novel vaccine versus carboplatin after amputation for canine appendicular osteosarcoma
Ethos Veterinary Health · USA
Now enrolling patients
What is being offered: Appendicular OSA; age >=1 year, >=44 lb, otherwise in good general health; cytologic/histologic confirmation. Current Ethos owner page lists 9 enrolling hospitals. An older AVMA registry listing contains additional historical sites; those are not promoted without current site-level confirmation.
Who may qualify: Confirmed cancer diagnosis required; Min weight lb: 44; Active tumor required; Appendicular location; Min age years: 1; Planned amputation
Costs / coverage: 🟡 Partially funded. All study-related visits are covered, including up to $4,000 toward amputation.
Contact: Contact participating Ethos hospital through official study page.
BI705564 oral BTK inhibitor for newly diagnosed canine B-cell lymphoma
Multicenter — University of Missouri + CASE / BI 705564 field trial · USA
Currently enrolling
What is being offered: Investigational oral BTK inhibitor BI705564
Who may qualify: Confirmed cancer diagnosis required; Min weight kg: 10; Max weight kg: 50; Measurable; Min age years exclusive: 1; Peripheral bcell lymphoma stage ii to iv
Costs / coverage: 🟢 Fully funded after enrollment. Screening bloodwork, urinalysis, chest X-rays, abdominal ultrasound, flow cytometry and the IDEXX Cancer Dx Panel are covered; once enrolled, the study is fully funded.
What is being offered: Randomized lymphoma treatment under an Ethos oncologist plus genomic/biomarker sampling
Who may qualify: Confirmed cancer diagnosis required; Prior chemo; Active tumor required; Lymphoma response: First relapse after remission; More than one relapse; Planned chemo
Costs / coverage: 🟡 Partially funded. Study provides screening and scheduled laboratory testing plus up to $4,500 toward chemotherapy, exams, diagnostics and medications for chemotherapy-related side effects.
Contact: CASE Clinical Trials — CASEtrials@ethosvet.com; 303-545-2273
Participating locations
Metropolitan Veterinary Hospital, 1053 S Cleveland-Massillon Rd, Akron, OH 44321
CARE Center, 6995 E Kemper Rd, Cincinnati, OH 45249
Ethos-PUSH precision-medicine umbrella study for splenic hemangiosarcoma
Ethos Discovery / multicenter specialty hospitals · USA
Open / currently enrolling
What is being offered: Phase 1 splenectomy/hemoabdomen study; dogs confirmed with non-metastatic splenic HSA can continue to fully funded active-treatment Phase 2, with treatment assigned among doxorubicin, doxorubicin+rapamycin, doxorubicin+sorafenib, or oral paclitaxel regimens.
Who may qualify: No metastasis; Active tumor required; Splenic primary; Planned surgery; Pre splenectomy; Min weight kg exclusive: 5; Max weight kg exclusive: 45
Costs / coverage: 🟡 Partially funded overall. Phase 1 provides $1,000 toward splenectomy; owners remain responsible for other initial surgical/screening costs. Dogs subsequently confirmed with splenic HSA and no metastases can enter fully funded Phase 2 (> $10,000 value). Sponsor states up to $3,000 for study-related side effects.
Contact: Ethos Discovery enrollment form / participating hospital; CASE: 303-545-2273
A listing here does not mean every pet will qualify. Enrollment can change, and the study team makes the final decision after reviewing your pet’s diagnosis, records and previous treatment.
Have the pathology report, recent imaging and treatment history ready. Ask whether a referral is required, which visits must happen in person and what the study pays for before making travel plans.
